Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase

Acta Pharmacologica Sinica

Volumn 31, Issue 1, 2010, Pages 93-101

  Wu, Jun ^a,b   Hu, Cheng Ping ^a   Gu, Qi Hua ^a   Li, Ye Peng ^a   Song, Min ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin resistance; Death associated protein kinase; Lung cancer; Trichostatin A

Indexed keywords

CISPLATIN; DEATH ASSOCIATED PROTEIN KINASE; RECOMBINANT ENZYME; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; UP-REGULATION;

EID: 74549205217     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.183     Document Type: Article

References (37)

1. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-9.
2. Bria E, Cuppone F, Cecere FL, Milella M, Nisticò C, Cognetti F, et al. Adjuvant chemotherapy for non-small cell lung cancer. J Thorac Oncol 2007; 2: S7-11.
3. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97. (Pubitemid 41007845)
4. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles- Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association ANITA): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27.
5. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63: 12-31.
6. Losert D, Pratscher B, Soutschek J, Geick A, Vornlocher HP, Müller M, et al. Bcl-2 downregulation sensitizes non small cell lung cancer cells to cisplatin, but not to docetaxel. Anticancer Drugs 2007; 18: 755-61.
7. Yang H, Fu JH, Hu Y, Huang WZ, Zheng B, Wang G, et al. Influence of siRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells. J Int Med Res 2008; 36: 734-47.
8. Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007; 8: 286-98.
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
10. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008; 3: 28-37.
11. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121: 656-65.
12. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005; 12: 482-91.
13. Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, Roessner A, et al. Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med 2008; 12: 607-21.
14. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp 1996; 5: 245-53.
15. Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A, et al. Trichostatin A up-regulates p73 and induces Baxdependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther 2008; 7: 1410-9.
16. Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 2006; 16: 563-8.
17. Karagiannis TC, Smith AJ, El' Osta A. Radio- and chemo-sensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor trichostatin A. Hell J Nucl Med 2004; 7: 184-91.
18. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-3645
19. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2- related protein Bad. Brain Tumor Pathol 2001; 18: 109-114
20. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-443
21. Zhang HT, Feng ZL, Wu J, Wang YJ, Guo X, Liang NC, et al. Sodium butyrate-induced death-associated protein kinase expression promote Raji cell morphological change and apoptosis by reducing FAK protein levels. Acta Pharmacol Sin 2007; 28: 1783-90.
22. Cohen O, Kimchi A. DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer. Cell Death Differ 2001; 8: 6-15.
23. Bai T, Tanaka T, Yukawa K, Umesaki N. A novel mechanism for acquired cisplatin-resistance: suppressed translation of deathassociated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells. Int J Oncol 2006; 28: 497-508.
24. Grare M, Mourer M, Fontanay S, Regnouf-de-Vains JB, Finance C, Duval RE. In vitro activity of para-guanidinoethylcalix4 arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria. J Antimicrob Chemother 2007; 60: 575-81.
25. Zhang HT, Wu J, Zhang HF, Zhu QF. Efflux of potassium ion is an important reason of HL-60 cells apoptosis induced by Tachyplesin J. Acta Pharmacol Sin 2006; 27: 1367-74.
26. McKeague AL, Wilson DJ, Nelson J. Staurosporine-induced apoptosis and hydrogen peroxide-induced necrosis in two human breast cell lines. Br J Cancer 2003; 88: 125-31.
27. Zhang MC, Hu CP, Chen Q. Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells. Zhonghua Zhong Liu Za Zhi 2006; 28: 408-12.
28. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, Oksenberg D. Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia. J Biol Chem 2005; 280: 42290-9.
29. Jin Y, Blue EK, Gallagher PJ. Control of death-associated protein kinase (DAPK) activity by phosphor ylation and proteasomal degradation. J Biol Chem 2006; 281: 39033-40.
30. Pelled D, Raveh T, Riebeling C, Fridkin M, Berissi H, Futerman AH, et al. Death-associated protein (dap) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J Biol Chem 2002; 277: 1957-61.
31. Raveh T, Berissi H, Eisenstein M, Spivak T, Kimchi A. A functional genetic screen identifies regions at the C-terminal tail and deathdomain of death-associated protein kinase that are critical for its proapoptotic activity. Proc Natl Acad Sci USA 2000; 97: 1572-7.
32. Gessner C, Liebers U, Kuhn H, Stiehl P, Witt C, Schauer J, et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of non small cell lung cancer. Eur Respir J 2002; 19: 134-40.
33. Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. Mol Cancer Res 2004; 2: 685-91.
34. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitorinduced apoptosis. Adv Exp Med Biol 2008; 615: 261-98.
35. Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 2008; 20: 639-49.
36. Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH, Ilstrup SJ. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther 2005; 4: 603-11.
37. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak-Kroizaman T, et al. DAP-kinase participates in TNF-α- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 1999; 146: 141-148